viewRevive Therapeutics

Revive Therapeutics taps Mount Sinai epidemiologist to advise coronavirus studies, data analysis

Joel Moody brings more than 15 years of clinical research experience in oncology, sickle cell disease, human T-Lymphotropic virus, cholera and tuberculosis

Scientist wearing PPE using a microscope
Revive's Phase 3 clinical trial is evaluating bucillamine in as many as 1,000 patients with mild-to-moderate COVID-19

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) announced Wednesday that Mount Sinai epidemiologist Joel Moody will serve as a medical and clinical advisor to assist with the clinical data analysis of the ongoing US Phase 3 clinical trial of bucillamine in patients with mild-to-moderate COVID-19.

Moody brings more than 15 years of clinical research experience in oncology, sickle cell disease, human T-Lymphotropic virus, cholera and tuberculosis. During his career, he has helped to launch and manage global phase I - IV clinical studies, including large scale morbid-mortality trials. 

In addition to working with the data from the US Food and Drug Administration trial of bucillamine, he will also help expand the company’s coronavirus studies in Canada.

READ: Revive Therapeutics in research collaboration to develop psilocybin to treat cancer and discover novel uses of undisclosed psychedelic compounds

"We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada," CEO Michael Frank said in a statement. "Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Moody is also a lecturer at the University of Toronto.

“I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19,” Moody said.

The Phase 3 study is testing bucillamine in as many as 1,00 patients randomized 1:1:1 to receive bucillamine 100 milligrams (mg) three times a day (TID), bucillamine 200 mg TID, or placebo TID for up to 14 days. An analysis of the initial patients will be conducted to determine the better-performing bucillamine arm to be used in the remainder of the trial. 

The company expects more than 200 patients to have completed the study by the end of the year. 

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Revive Therapeutics

Price: 0.42 CAD

Market: CSE
Market Cap: $99.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...


Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 30/6/20

2 min read